Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per ... Read More
EC grants expanded approval for Amgen’s BLINCYTO in pediatric acute lymphoblastic leukemia treatment
In a significant development for pediatric oncology, the European Commission (EC) has approved an expanded indication for Amgen’s BLINCYTO (blinatumomab) as a monotherapy treatment for ... Read More